Greenwich LifeSciences
GLSI | NASDAQ
$13.76
-$1.18 (-7.90%)
At close: Nov 16, 2026, 4:00 PM ET
$13.95
+$0.19 (+1.38%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-7.90%
(1D)No price chart data available for 1D timeframe.
Rating
24.5
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #942/1021 (Top 92%)
Key Statistics
Market Data
Market Cap $201.97M
1D Range
13.52 14.81
52W Range
7.85 33.57
Valuation (TTM)
PE -8.94
PB 64.80
EV/EBITDA -8.91
Valuation (NTM)
Forward PE N/A
Forward PEG -0.74
Price Target $50.00
Cash Flow
FCF Yield -6.2%
SBC Adj. FCF Yield -8.4%
SBC Impact -36.6%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y -30.5% |
-29.7%
FCF 3Y | 5Y -30.8% |
-20.1%
Returns
ROA -244.3%
ROE -793.8%
ROIC -701.5%
Financial Health
Net Cash
$8.88M
Current Ratio 1.54
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer...
Sector Healthcare
Industry Biotechnology
Employees 13
IPO Date Sep 25, 2020
Website greenwichlifesciences.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
1
Consensus
Buy
Price Target
$50.00
Upside
+263.37%
Buy (1)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove GLSI